

Date: June 23, 2026

To,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400051
Maharashtra, India.

Symbol: FABTECH

BSE Limited

Listing Department
Floor 25, P J Towers,
Dalal Street, Mumbai – 400001
Maharashtra, India.

Scrip Code: 544558

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation Investors/Analysts Meeting, “The Growth Exchange 2026- Niveshak Samvad Roadshow”, to be held on Wednesday, June 24 ,2026 from 05:30 p.m.to 06:30 p.m. (IST).

Request you to take the same on record.

Thank you.

**Yours faithfully,
For Fabtech Technologies Limited**

**Hemant Mohan Anavkar
Executive Director
DIN: 00150776**

Encl.: As mentioned above

INVESTOR PRESENTATION · FY26

India's Global Life Sciences Infrastructure Platform

Engineering medicinal sovereignty across the pharma-emerging geographies.

BSE Main Board · "FABTECH" • 62+ countries • 500+ projects delivered

WHAT FABTECH DOES

We build the factories that make medicines.

Every vaccine, IV solution and tablet is made inside a certified, sterile facility. Fabtech is the **end-to-end turnkey provider** that designs, engineers, builds and validates those facilities — for pharma, biotech and healthcare clients worldwide.

What makes us rare: we **manufacture the core systems in-house** — Process, Air and Water — under one roof, so quality, speed and cost stay in our control.

Process

Manufacturing & process equipment integrated into the production line.

Air


Cleanrooms & HVAC — the controlled environment medicines are made in.

Water

Purified-water & utility systems engineered to pharmacopoeia grade.

One integrated group platform.

Three decades of engineering, presence across 62+ countries, and **78% of revenue from MENA, GCC & ECO Zone** markets — an asset-light model that scales through in-house arms and strategic partners.



MANUFACTURING CAPABILITIES

Six capability domains, built in Fabtech group.

Every solution is custom-designed and built at our own facilities — covering OSD, sterile liquids, vaccines, oncology, hormones & biosimilars.

Cleanroom

Modular & bio-cleanrooms, HVAC and internal infrastructure.

Sterilisation

Air & contained sterilisation, tunnels and cleanroom equipment.

Containment

Isolation & containment for process, packaging and QC/QA.

Water & Utilities

Purified water, pure steam & WFI generation and distribution.

Process



Powder processing, OSD & tablet coating, lab to production scale.

Custom-built

Designed & manufactured in-house for each client's challenge.

SERVICE OFFERING

Turnkey engineering across the full value chain.



From advisory to post-compliance support — start-to-end services covering the entire project value chain.

THE FY26 STORY

A resilient year, and a wider runway ahead.

Operational continuity

Project execution momentum held strong through freight volatility, geopolitical disruption and elevated input costs.

Growth visibility

A ₹900+ Cr order book underpins revenue for the periods ahead, backed by a robust enquiry pipeline.

Regional expansion

UAE & Saudi localisation, JVs and a European acquisition extend reach into premium, high-margin markets.

War Impact

Near-term conflict disrupts delivery schedules and lifts input costs but reshapes global supply chains in our favour — unlocking **outsized long-term gains**.

FY26 RESULTS · YEAR ENDED 31 MARCH 2026

Scaling, with discipline.

Standalone results ₹
in Crore | vs FY25

Revenue from Operations

₹410.77

↑ 25.7% YoY

vs ₹326.67 in FY25

Operational Profit

₹36.60

↑ 17.0% YoY

vs ₹31.27 in FY25 due to 16.66%
of TSA sale.

Reported Net Profit (PAT)

₹38.36

Normalised exceptionals

vs ₹46.45 in FY25

Order Book

₹900+

Healthy visibility

Confirmed, ready to execute

STRATEGIC UPDATE

Resilient delivery, an expanding platform.

Strong order book position

Consolidated order book of **₹900+ Cr as of 31 March 2026** — providing strong revenue visibility and growth momentum.

Resilient performance amid volatility

Navigated logistics disruptions, freight challenges and input-cost pressures with minimal impact — a robust execution model.

Key strategic wins & expansion

Entry into the **Animal Health** segment; KSA vaccine & advanced pharma projects; large-scale Africa pharma & infrastructure wins.

Positioning & outlook

Expanding across high-growth sectors & geographies into a scalable, diversified platform — positive outlook on a robust pipeline of complex, high-value projects.

ORDER BOOK & PIPELINE

Visibility you can underwrite.

A confirmed book funds execution for the coming periods, while a step-change in conversion turns a deep enquiry pipeline into structural growth.

Consolidated order book · as of 31 Mar 2026

₹900+ Cr

Confirmed orders ready for execution.

Conversion target

10% → **20%**

Improving post European acquisition for structural visibility.

STRATEGIC PROJECT WINS

New mandates across high-growth markets.

Marquee wins expanding our sector and geographic reach — anchoring the ₹900+ Cr order book.

WEST AFRICA

Oral Solid Dosage Facility

USD 7.05M

~₹63.6 Cr

SCOPE

Supply, installation & commissioning of full infrastructure.

TIMELINE

23–27 months

IMPACT

Expands West Africa footprint; supports local medicine manufacturing.

SAUDI ARABIA

Animal Vaccine Project

USD 7.8M

~₹65.5 Cr

SCOPE

Turnkey cleanroom, HVAC, MEP & utilities through to handover.

TIMELINE

11 months

IMPACT

Entry into high-growth animal health; strengthens KSA presence.

NORTH AFRICA

Next-Gen Veterinary Facility

₹49–52 Cr

Project value

SCOPE

EU-GMP-compliant veterinary formulations facility.

TIMELINE

Targeted for completion by Q1 FY27

IMPACT

Enables EU & African exports; long-term regional reference value.

BENCHMARK PROJECTS

Firsts and largests that competitors can't easily follow.

Each landmark project builds regulatory credibility — creating reference moats, entry barriers and a repeat pipeline.

LARGEST

IV Solution Facility

Saudi Arabia

FIRST

Biosimilars Facility

Algeria

UAE'S ONLY

USFDA-Approved Facility

United Arab Emirates

FIRST

Oncology Project

Saudi Arabia

FIRST

Flu Vaccine Project

Egypt

GLOBAL PRESENCE

Global engineering, local execution.

62+

countries delivered

500+

projects completed

2000+

specialised installations

India

Engineering & manufacturing base

UAE

Regional HQ & USFDA facility

Saudi Arabia

IV & oncology facilities

Jordan

MENA project delivery

Egypt

Flu vaccine project

Algeria

First biosimilars facility

Nigeria

West Africa expansion

GCC · MENA · Africa
Core growth corridor

GROWTH STRATEGY · PLAN AHEAD

Three levers to compound from here.

European Acquisition

Strengthening brand presence, entering premium markets, expanding margins and diversifying the product portfolio.

Joint Ventures

Strengthening presence in KSA, East Africa & North Africa with trusted local partners.

Working-Capital Strength

Improved liquidity for smoother cycles — enabling faster project acquisition and aggressive growth.

MARKET OPPORTUNITY

A large, structurally-funded addressable market.

Fabtech's scope covers **60%+ of project spend** — Air, Water, Process, Cleanrooms and Utilities.

Global TAM

\$180B

Turnkey pharma & biotech projects, growing at ~8% CAGR.

Fabtech SAM

\$28–30B

Core geographies: GCC, Africa & MENA.

KSA Build-Out

\$15B+

Pharma manufacturing investment planned to 2030.

Africa

\$60B+

Medicine-production facilities, WHO / Global Fund backed to 2040.

Source: Grand View Research (Pharmaceutical Manufacturing Market Report); regional capex estimates.

Local where it counts — and the advantage is ours.

By becoming a **domestic company** in the UAE and Saudi Arabia, we unlock a natural tax advantage and the full weight of being local.

Natural tax advantage

Domestic status lowers our effective tax burden — flowing straight through to PAT.

Local-content preference

Eligible for tenders, incentives & mandates reserved for in-country manufacturers — KSA local content & UAE in-country value.

Proximity & trust

Local presence means faster execution, regional supply and preferred-partner status with governments.

EXECUTION CONTROL · PEB SCOPE

Own the building, own the timeline.

The challenge today

Project duration **2–3 years**

Fabtech shipment (~90%) **1–1.5 years**

The lag isn't us — it's clients not being ready with **civil infrastructure**.

Our move — take the PEB scope

By owning the **pre-engineered building** scope, we control the civil works, the timeline and the deliverables of the entire project — end to end.

Larger ticket size

Efficient end-to-end execution


Higher volume & revenue

Full delivery control

MARGIN EXPANSION ROADMAP

From 8–9% to 11–13% PAT margin.

Three structural levers compound straight into the bottom line.



BUILDING LONG-TERM VALUE

We are not a quarter-to-quarter story.

We build multi-year, mission-critical facilities — and compound shareholder value across cycles.

FY27 standalone revenue

₹500 Cr

FY27 standalone PAT

₹45 Cr

Current-year trajectory — ~9% PAT margin, expanding toward 11–13%.

FTL 2030 VISION

Climbing the value curve to advanced-technology facilities.

Beyond conventional pharma — turnkey design-and-build for the most complex, highest-value life-sciences builds.

Medical Diagnostics

Vaccines

Biotech

Cell & Gene Therapy

High-Tech Facilities

How we enter these markets: Local domestic status • PEB-led delivery control • Reference moat • Capital via JVs & acquisition

FTL 2030 VISION · THE OPPORTUNITY

A 15-year structural opportunity — and the platform built to capture it.

15-year runway

A structural shift toward regional medicinal sovereignty.

Scalable model

In-house ecosystem that scales across formats and geographies.

Reference-led moat

Every landmark project compounds credibility and pipeline.



Fabtech[®]
Technologies Limited
Life Engineering™

We enable the world to manufacture life-saving medicines — without having made a single pill.

Thank you. • BSE Main Board • “FABTECH” • Life Engineering™